Mesa 3. Tratamiento en la EPOC

1. Mesa 3. Tratamiento

2. Mesa 3. Tratamiento
Dr. Bernardino
Alcázar Navarrete
Hospital de Alta Resolución de Loja.
Granada

3. Mesa 3. Tratamiento
Mesa 3
Tratamiento

4. Mesa 3. Tratamiento
GOLD guidelines, 2015

5. Mesa 3. Tratamiento
Miravitlles et al. Arch Bronconeumol 2014

6. Mesa 3. Tratamiento
Bateman et al. ERJ 2013

7. Mesa 3. Tratamiento
Dransfield, Lancet Resp Med 2013

8. Mesa 3. Tratamiento
Sin et al, Thorax 2010

9. Mesa 3. Tratamiento
Pascoe, Lancet Resp Med 2015

10. Mesa 3. Tratamiento
Magnussen et al. NEJM 2014

11. Mesa 3. Tratamiento

12. Mesa 3. Tratamiento
Dr. José Luis López-Campos
I [SEPAR] Utilidad de la vacunación antineumocócica de 13
serotipos en la prevención de exacerbaciones graves de
EPOC
I [ATS] QVA 149 Improves Lung Function To A Greater Extent
Than Monocomponents In Patients With Moderate-To-
Severe COPD: The FLIGHT 1 Study

13. Mesa 3. Tratamiento
Dr. Joan Serra
I [ATS] Effects Of 6 Weeks’ Treatment With Once-Daily
Tiotropium And Olodaterol Fixed-Dose Combination On
Inspiratory Capacity And Exercise Endurance In Patients With
COPD: The MoractoTM Studies
I [ATS] Withdrawal Of Inhaled Corticosteroids And
Exacerbations Of COPD:The WISDOM Phenotyping Substudy
I [ERS] Triple therapy of umeclidinium and inhaled
corticosteroid/long-actingβ2-agonist (ICS/LABA) vs placebo +
ICS/LABA in GOLD D patients

14. Mesa 3. Tratamiento
Dr. Juan Antonio Riesco
I [ATS] Inhaled Corticosteroids And Risk Of Incident Pneumonia
And Mortality In Chronic Obstructive Pulmonary Disease (COPD)
Patients: A Systematic Review And Meta-Analysis
I [ATS] COPD Patient Clusters That Benefit Most From Fluticasone
Furoate Added To Vilanterol (FF/VI) vs Vilanterol (VI)
I [ERS] Effect of exacerbation history and ICS use on outcomes in
COPD patients from the TIOSPIR™ trial
I [ERS] Tiotropium efficacy and exacerbation risk in patients with
different blood eosinophil levels

15. Mesa 3. Tratamiento
Dr. Carlos Amado
I [ATS] Stepwise Withdrawal Of Inhaled Corticosteroids in
COPD Patients Receiving Dual Bronchodilators: Lung Function
Reduction In The WISDOM Study
I [ERS] Long-term efficacy of A1-PI therapy in RAPID and
RAPID extension trials
I [ATS] QVA 149 Provides Superior Improvement In Lung
Function vs Its Monocomponents In Patients With Moderate-
To-Severe COPD: The FLIGHT 2 Study

16. Mesa 3. Tratamiento
Muchas gracias
por su atención